| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2019 - 2023 |
| 乐鱼体育官网 Size (2025) | USD 204.91 Million |
| 乐鱼体育官网 Size (2030) | USD 252.92 Million |
| CAGR (2025 - 2030) | 4.30 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Zimbabwe Pharmaceutical 乐鱼体育官网 Analysis
The Zimbabwe Pharmaceutical 乐鱼体育官网 size is estimated at USD 204.91 million in 2025, and is expected to reach USD 252.92 million by 2030, at a CAGR of 4.3% during the forecast period (2025-2030).
The COVID-19 impact on the pharmaceutical industry in Zimbabwe was significant. The industry saw an increased demand for therapeutics to treat COVID-19-infected patients, which further led to an increase in the large-scale manufacturing of pharmaceutical products in the country. As the supply chain between the other regions of the world and Zimbabwe was disrupted due to lockdown measures, the local manufacturers played a critical role during the COVID-19 pandemic. For instance, according to a research article published in the Journal of Public Health International in May 2021, the disruption of medical supplies such as pharmaceuticals during the pandemic provided a great opportunity for Zimbabwe to be less dependent on foreign medical supplies, thereby increasing the local manufacturing of therapeutics. However, post-pandemic, the sector has been recovering well since supply chain restrictions were lifted. An increase in the supply of medication from global manufacturers and a rise in initiatives from the key 乐鱼体育官网 players, among others, have been leading the 乐鱼体育官网 recovery. Moreover, the Zimbabwean Ministry of Health and Child Care (MOHCC) took measures to strengthen the country's ability to produce medical supplies through various organizations such as Varichem, CAPS, Natpharma, and Avail Pharmaceuticals during the pandemic and is expected to impact the 乐鱼体育官网's growth in post-pandemic phase. Thus, as per the analysis, the abovementioned factors significantly affected the 乐鱼体育官网's growth.
With an ageing population and rising rates of chronic disease, Zimbabwe's pharmaceutical sector is poised for expansion. According to the United Nations Population Fund report for 2022, the population aged 65 years and older in Zimbabwe was estimated at 3 million in 2022. The senior population is more likely to suffer from chronic conditions like cardiovascular disease, cancer, and gastrointestinal disorders, hence this demographic shift is predicted to boost the need for drugs in Zimbabwe.
Furthermore, in June 2021, the Zimbabwean government launched the 2021-2025 Pharmaceutical Manufacturing Strategy to improve the local production of drugs, thereby increasing the availability of the country's essential medicines and exporting excess drugs. In addition, in March 2021, the Republic of Zimbabwe became the 19th African Union (AU) Member State to sign the Treaty to establish the African Medicines Agency (AMA). This move may enable a favorable regulatory environment for pharmaceutical research and development, local production, and trade across countries on the African continent. Likewise, in April 2022, the University at Buffalo and the University of Zimbabwe entered a partnership to train future HIV researchers in Zimbabwe and received a USD 1.4 million grant from the National Institutes of Health (NIH). Such initiatives are expected to drive 乐鱼体育官网 growth over the forecast period.
Therefore, the demand for effective and novel therapeutics is expected to grow in the coming years. Thus, the abovementioned factors are anticipated to aid the 乐鱼体育官网's growth over the forecast period. However, the stringent regulatory framework is expected to restrain the growth.
Zimbabwe Pharmaceutical 乐鱼体育官网 Trends
The Generic Drugs Segment Holds a Significant Share and is Expected to Continue the Trend During the Forecast Period
The major driving factors for the generic drugs segment are the rising initiatives by key players, the launch of new products aimed at treating various illnesses, the growing geriatric population, the rising prevalence of chronic diseases such as cardiovascular diseases, cancers, and autoimmune diseases, and the growing awareness about the use of prescription drugs in the country. In addition, according to the study published in Therapeutic Innovation & Regulatory Science in January 2021, more than 80% of the drugs sold in Zimbabwe are generic drugs.
The prevalence of chronic diseases such as cancers is increasing in Zimbabwe, thus boosting the demand for advanced therapeutics and driving the 乐鱼体育官网 segment due to the affordability of these drugs. As an example, the Zimbabwe Human Papillomavirus and Related Cancers Fact Sheet 2021 reports that there are 3,043 new instances of cervical cancer in Zimbabwe per year. The high rate of cervical cancer in the country is likely to raise the consumption of generic medications, which could boost demand within the predicted time frame.
Furthermore, in November 2022, the deputy minister of health and child care of zimbabwe urged pharmaceutical firms to encourage the manufacturing of generic medications in order to lower the cost of the nation's medical imports. Such initiatives will lead to increased production of generic drugs, thereby lead to increased adoption, driving the segment growth.
Therefore, owing to the above-mentioned factors, the generic drugs segment is expected to grow over the forecast period.
Understand The Key Trends Shaping This 乐鱼体育官网
Download PDF
General Anti-infective Systemic Segment is Expected to Hold a Significant Share in the 乐鱼体育官网
The factors driving the growth of this segment include the rising prevalence of infectious diseases such as HIV, HPV, and TB and the rising launch of drugs for infectious diseases, among others.
According to the CDC, in 2021, the estimated prevalence of HIV in Zimbabwe among the 15-49 year age group was found to be 11.6%, and the number of adults above the age of 15 on antiretroviral therapy in 2021 was 1,136,246. Therefore, the huge prevalence of HIV and the dependence on antiviral therapy are expected to drive segment growth over the forecast period.
Furthermore, the rising approvals of antiinfective drugs in Zimbabwe are expected to drive the segment's growth. For instance, in October 2021, the Medicines Control Authority of Zimbabwe approved three private hospitals and three private pharmacies to dispense Ivermectin, a broad-spectrum anti-parasitic drug, for the prevention and treatment of COVID-19. Therefore, increasing approvals from the government of Zimbabwe are expected to drive the growth of this segment.
Thus, the rising infectious diseases and the rising approvals for anti-infective therapies are likely to boost the segment's growth over the analysis period.
Get Analysis on Important Geographic 乐鱼体育官网s
Download PDF
Zimbabwe Pharmaceutical Industry Overview
The Zimbabwe pharmaceutical 乐鱼体育官网 is highly competitive and consists of several major players. In terms of 乐鱼体育官网 share, a few major players are currently dominating the 乐鱼体育官网. Some prominent players are vigorously making acquisitions and joint ventures with other companies to consolidate their 乐鱼体育官网 positions in the country. Some of the companies in this 乐鱼体育官网 include DatLabs (Pvt) Ltd., Pharmanova, CosPharma, Zim Laboratories Limited, and B. Braun SE, among others.
Zimbabwe Pharmaceutical 乐鱼体育官网 Leaders
-
Pharmanova
-
Zim Laboratories Limited
-
Datlabs
-
Caps (Pvt) Ltd
-
B. Braun
- *Disclaimer: Major Players sorted in no particular order
Need More Details on 乐鱼体育官网 Players and Competiters?
Download PDF
Zimbabwe Pharmaceutical 乐鱼体育官网 News
- October 2022: Zimbabwe approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV prevention.
- October 2022: China handed a state-of-the-art pharmaceutical warehouse to the Zimbabwean government, which is expected to boost Zimbabwe's drug storage capacity and improve its health delivery system.
Zimbabwe Pharmaceutical Industry Segmentation
As per the scope of the report, pharmaceuticals are referred to as prescription and non-prescription drugs. These medicines can be bought by an individual with or without the doctor's prescription and are safe for consumption for various illnesses with or without the doctor's consent. The Zimbabwe Pharmaceutical 乐鱼体育官网 is Segmented by ATC/Therapeutic Category (Blood and Hematopoietic Organs, Digestive Organ and Metabolism, Cardiovascular System, Nervous System, Musculoskeletal Organ, General Anti-infectives Systemic, Respiratory System, and Other ATC/Therapeutic Categories) and Drug Type (Prescription Type (Branded and Generic), and, OTC Drugs). The report offers the value (USD million) for the above segments.
| By ATC/Therapeutic Category | Blood and Hematopoietic Organs | ||
| Digestive Organ and Metabolism | |||
| Cardiovascular System | |||
| Nervous System | |||
| Musculoskeletal Organ | |||
| General Antiinfectives Systemic | |||
| Respiratory System | |||
| Other ATC/Therapeutic Categories | |||
| By Drug Type | Prescription Drugs (Rx) | Branded | |
| Generic | |||
| OTC Drugs | |||
Need A Different Region or Segment?
Customize Now
Zimbabwe Pharmaceutical 乐鱼体育官网 Research FAQs
How big is the Zimbabwe Pharmaceutical 乐鱼体育官网?
The Zimbabwe Pharmaceutical 乐鱼体育官网 size is expected to reach USD 204.91 million in 2025 and grow at a CAGR of 4.30% to reach USD 252.92 million by 2030.
What is the current Zimbabwe Pharmaceutical 乐鱼体育官网 size?
In 2025, the Zimbabwe Pharmaceutical 乐鱼体育官网 size is expected to reach USD 204.91 million.
Who are the key players in Zimbabwe Pharmaceutical 乐鱼体育官网?
Pharmanova, Zim Laboratories Limited, Datlabs, Caps (Pvt) Ltd and B. Braun are the major companies operating in the Zimbabwe Pharmaceutical 乐鱼体育官网.
What years does this Zimbabwe Pharmaceutical 乐鱼体育官网 cover, and what was the 乐鱼体育官网 size in 2024?
In 2024, the Zimbabwe Pharmaceutical 乐鱼体育官网 size was estimated at USD 196.10 million. The report covers the Zimbabwe Pharmaceutical 乐鱼体育官网 historical 乐鱼体育官网 size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Zimbabwe Pharmaceutical 乐鱼体育官网 size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Pharmaceutical in Zimbabwe Industry Report
The Zimbabwe pharmaceutical 乐鱼体育官网 is on a trajectory of significant growth, fueled by an increase in eye-related disorders, advancements, and investments in the sector, and the advent of global players bringing novel therapies for infectious diseases. Despite challenges like economic downturns affecting affordability, opportunities such as government initiatives to boost local production for domestic and export needs are promising. The 乐鱼体育官网, dominated by antiviral and anti-infective drug segments, caters to the treatment of diseases like HIV, tuberculosis, and malaria, with hospital pharmacies playing a pivotal role in distribution. This evolving landscape underscores the potential for considerable expansion, relying on strategic innovation and adherence to international standards to overcome hurdles and meet health demands efficiently. For detailed insights, Mordor Intelligence鈩� Industry Reports provide comprehensive analysis, including 乐鱼体育官网 share, size, revenue growth rate, and a forecast outlook, available as a free report PDF download.
